keyword
https://read.qxmd.com/read/38646550/irritable-bowel-syndrome-in-medical-students-at-a-peruvian-university-a-cross-sectional-study
#1
JOURNAL ARTICLE
Pedro P Quiroga-Castañeda, Iván Berrios-Villegas, Danai Valladares-Garrido, Víctor J Vera-Ponce, J Pierre Zila-Velasque, César Johan Pereira-Victorio, Mario J Valladares-Garrido
BACKGROUND: Irritable Bowel Syndrome has emerged as a significant public health challenge, particularly relevant in medical students due to the high demands of their studies, academic stress, and susceptibility to eating disorders. Nevertheless, conclusive evidence regarding the factors associated with Irritable Bowel Syndrome in the Latin American student population remains limited. The objective of this study was to determine the prevalence and factors associated with Irritable Bowel Syndrome in Human Medicine students at a university in northern Peru...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38646212/a-review-of-the-efficacy-of-the-low-fermentable-oligosaccharides-disaccharides-monosaccharides-and-polyols-fodmap-diet-in-managing-gastrointestinal-symptoms-related-to-cancer-treatment
#2
REVIEW
Arwa S Almasaudi
The low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet, designed to alleviate symptoms in individuals with irritable bowel syndrome (IBS), focuses on limiting the consumption of poorly absorbed fermentable carbohydrates known as FODMAP. These FODMAP are believed to be the primary triggers for food-related gastrointestinal symptoms in functional gastrointestinal disorders. However, there is currently insufficient direct evidence investigating the role of low FODMAP diets in cancer patients undergoing treatment...
March 2024: Curēus
https://read.qxmd.com/read/38646157/a-systematic-review-fecal-bacterial-profile-in-patients-with-irritable-bowel-syndrome-analyzed-with-the-ga-map-dysbiosis-test-based-on-the-16s-rrna-gene-of-bacterial-species-or-groups
#3
REVIEW
Erica Sande Teige, Urd Sortvik, Gülen Arslan Lied
PURPOSE: The diagnosis of irritable bowel syndrome (IBS) is based on symptom-based criteria due to lack of reliable disease-specific biomarkers. Gut microbiota is perturbed in IBS and when comparing different methods used to analyze gut microbiota, the results might be obscured. Therefore, in this systematic review we aimed to investigate the profile of fecal bacterial markers and dysbiosis index (DI) in patients with IBS and IBS subgroups compared to healthy controls (HCs) conducted by the same method (GA-map Dysbiosis Test based on16S rRNA sequencing)...
2024: Clinical and Experimental Gastroenterology
https://read.qxmd.com/read/38645163/gpr37-modulates-the-severity-of-inflammation-induced-gi-dysmotility-by-regulating-enteric-reactive-gliosis
#4
Keiramarie Robertson, Oliver Hahn, Beatriz G Robinson, Arwa T Faruk, Mathangi Janakiraman, Hong Namkoong, Kwangkon Kim, Jiayu Ye, Estelle Spear Bishop, Randy A Hall, Tony Wyss-Coray, Laren S Becker, Julia A Kaltschmidt
The enteric nervous system (ENS) is contained within two layers of the gut wall and is made up of neurons, immune cells, and enteric glia cells (EGCs) that regulate gastrointestinal (GI) function. EGCs in both inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) change in response to inflammation, referred to as reactive gliosis. Whether EGCs restricted to a specific layer or region within the GI tract alone can influence intestinal immune response is unknown. Using bulk RNA-sequencing and in situ hybridization, we identify G-protein coupled receptor Gpr37 , as a gene expressed only in EGCs of the myenteric plexus, one of the two layers of the ENS...
April 12, 2024: bioRxiv
https://read.qxmd.com/read/38644084/prevalence-of-irritable-bowel-syndrome-and-other-functional-gastrointestinal-disorders-in-uruguay
#5
JOURNAL ARTICLE
V Guido, Y Pontet, V López, C Olano
INTRODUCTION AND AIMS: Irritable bowel syndrome (IBS) is one of the most frequent functional gastrointestinal disorders. Prevalence worldwide is estimated at 11%. There is little information on the prevalence of the other functional bowel disorders (FBDs). Our aim was to establish the prevalence of IBS and other FBDs according to the Rome IV criteria, in Uruguay. MATERIALS AND METHODS: An observational, population-based prevalence study was conducted. Data were collected through an online questionnaire, utilizing the Rome IV criteria...
April 20, 2024: Revista de Gastroenterología de México
https://read.qxmd.com/read/38643935/rome-iii-criteria-capture-higher-irritable-bowel-syndrome-snp-heritability-and-highlight-a-novel-genetic-link-with-cardiovascular-traits
#6
JOURNAL ARTICLE
Leticia Camargo Tavares, Esteban Alexander Lopera-Maya, Ferdinando Bonfiglio, Tenghao Zheng, Trishla Sinha, Francine Zanchetta Marques, Alexandra Zhernakova, Serena Sanna, Mauro D'Amato
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) shows genetic predisposition, and large-scale genome-wide association studies (GWAS) are emerging, based on heterogeneous disease definitions. We aimed at investigating the genetic architecture of IBS defined according to gold-standard Rome Criteria. METHODS: We conducted GWAS meta-analyses of Rome III IBS and its subtypes in 24,735 IBS cases and 77,149 asymptomatic controls from two independent European cohorts (UK Biobank and Lifelines)...
April 18, 2024: Cellular and Molecular Gastroenterology and Hepatology
https://read.qxmd.com/read/38643783/managing-irritable-bowel-syndrome-balancing-diet-and-pharmacotherapy
#7
JOURNAL ARTICLE
Uday C Ghoshal, Uzma Mustafa, Mahesh K Goenka
No abstract text is available yet for this article.
April 18, 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38643782/a-low-fodmap-diet-plus-traditional-dietary-advice-versus-a-low-carbohydrate-diet-versus-pharmacological-treatment-in-irritable-bowel-syndrome-carbis-a-single-centre-single-blind-randomised-controlled-trial
#8
JOURNAL ARTICLE
Sanna Nybacka, Hans Törnblom, Axel Josefsson, Johann P Hreinsson, Lena Böhn, Åsa Frändemark, Cecilia Weznaver, Stine Störsrud, Magnus Simrén
BACKGROUND: Dietary advice and medical treatments are recommended to patients with irritable bowel syndrome (IBS). Studies have not yet compared the efficacy of dietary treatment with pharmacological treatment targeting the predominant IBS symptom. We therefore aimed to compare the effects of two restrictive dietary treatment options versus optimised medical treatment in people with IBS. METHODS: This single-centre, single-blind, randomised controlled trial was conducted in a specialised outpatient clinic at the Sahlgrenska University Hospital, Gothenburg, Sweden...
April 18, 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38643709/tranilast-alleviates-visceral-hypersensitivity-and-colonic-hyperpermeability-by-suppressing-nlrp3-inflammasome-activation-in-irritable-bowel-syndrome-rat-models
#9
JOURNAL ARTICLE
Tsukasa Nozu, Hideyuki Arie, Saori Miyagishi, Masatomo Ishioh, Kaoru Takakusaki, Toshikatsu Okumura
Visceral hypersensitivity resulting from compromised gut barrier with activated immune system is a key feature of irritable bowel syndrome (IBS). Corticotropin-releasing factor (CRF) and Toll-like receptor 4 (TLR4) activate proinflammatory cytokine signaling to induce these changes, which is one of the mechanisms of IBS. As activation of the NLRP3 inflammasome by lipopolysaccharide (LPS) or TLR4 leads to release interleukin (IL)-1β, the NLRP3 inflammasome may be involved in the pathophysiology of IBS...
April 20, 2024: International Immunopharmacology
https://read.qxmd.com/read/38642511/effects-of-oral-administration-of-ondansetron-a-5-ht-3-receptor-antagonist-on-anxiety-related-behaviors-and-colonic-hypercontractility-in-repeated-stress-induced-mice
#10
JOURNAL ARTICLE
Affan Waemong, Sarunnuch Sattayachiti, Dania Cheaha, Nipaporn Konthapakdee
PURPOSE: Chronic psychological stress develops and exacerbates irritable bowel syndrome (IBS). 5-hydroxytryptamine (5-HT) via activation of intestinal 5-HT3 receptors involves impairment of intestinal functions. This study aimed to investigate the effects of ondansetron, a 5-HT3 receptor antagonist, on locomotor activity, anxiety-related behaviors, and colonic functions in repeated water avoidance stress. MATERIALS AND METHODS: Food intake and fecal pellet output (FPO) of sham stress (SS), water avoidance stress (WS), and water avoidance stress with oral administration of ondansetron (1 mg/kg BW) (WA) groups were monitored along the water avoidance stress protocol for 10 consecutive days...
April 18, 2024: Autonomic Neuroscience: Basic & Clinical
https://read.qxmd.com/read/38638935/influence-of-ethnic-origin-on-the-clinical-characteristics-and-intestinal-flora-of-irritable-bowel-syndrome-a-prospective-study-between-han-and-tibetan-patients
#11
JOURNAL ARTICLE
Xiao Ma, Hui Huan, Chao Liu, Hong Hu, Tao Ren
BACKGROUND: Few studies have focused on the clinical characteristics and intestinal flora of Tibetan patients with irritable bowel syndrome (IBS). The study aimed to compare the difference of between Tibetan and Han patients with IBS. METHODS: Patients who met inclusion and exclusion criteria were divided into the Tibet and Han groups. A simplified Gastrointestinal Symptom Rating Scale (GSRS)-based questionnaire was used to assess the IBS severity. Fecal samples from all subjects were collected for the analysis of gut microbiota using 16sRNA Illumina sequencing...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38632660/four-year-follow-up-of-psychiatric-and-psychosomatic-profile-in-patients-with-inflammatory-bowel-disease-ibd
#12
JOURNAL ARTICLE
Sara Gostoli, Francesco Ferrara, Ludovica Quintavalle, Sara Tommasino, Graziano Gigante, Maria Montecchiarini, Alessia Urgese, Francesco Guolo, Regina Subach, Angelica D'Oronzo, Annamaria Polifemo, Federica Buonfiglioli, Vincenzo Cennamo, Chiara Rafanelli
Psychological characterization of patients affected by Inflammatory Bowel Disease (IBD) focuses on comorbidity with psychiatric disorders, somatization or alexithymia. Whereas IBD patients had higher risk of stable anxiety and depression for many years after the diagnosis of the disease, there is a lack of studies reporting a comprehensive psychosomatic assessment addressing factors of disease vulnerability, also in the long-term. The objective of this investigation is to fill this gap in the current literature...
April 17, 2024: BMC Psychology
https://read.qxmd.com/read/38630738/efficacy-of-shu-yi-ning-chang-decoction-on-ibs-d-modulating-nr4a3-pathway-to-reduce-visceral-hypersensitivity
#13
JOURNAL ARTICLE
Yajing Guo, Qiongqiong Lu, Xiao-Jun Yang, Yuxi He, Yue Wu, Baijun Qin, Ting Li, Min Duan, Nvping Liu, Xin Wu, Yuanjun He
AIM OF THE STUDY: To evaluate the therapeutic effect of SYNC in diarrhea irritable bowel syndrome (IBS-D) and explore its underlying mechanism through transcriptomic sequencing (RNA-Seq). MATERIALS AND METHODS: A rat model of IBS-D was constructed to elucidate the effects of SYNC. Abdominal withdrawal reflex (AWR), fecal water content (FWC), and recording body weight were calculated to assess visceral sensitivity in rats. Histopathological changes in the colon and alterations in mast cell (MC) count were determined...
2024: PloS One
https://read.qxmd.com/read/38630015/a-randomized-double-blind-placebo-controlled-trial-to-evaluate-the-safety-and-efficacy-of-live-bifidobacterium-longum-cect-7347-es1-and-heat-treated-bifidobacterium-longum-cect-7347-ht-es1-in-participants-with-diarrhea-predominant-irritable-bowel-syndrome
#14
JOURNAL ARTICLE
S Srivastava, U Basak, M Naghibi, V Vijayakumar, R Parihar, J Patel, P S Jadon, A Pandit, R R Dargad, S Khanna, S Kumar, R Day
To determine the efficacy of the probiotic Bifidobacterium longum CECT 7347 (ES1) and postbiotic heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in improving symptom severity in adults with diarrhea-predominant irritable bowel syndrome (IBS-D), a randomised, double-blind, placebo-controlled trial with 200 participants split into three groups was carried out. Two capsules of either ES1, HT-ES1 or placebo were administered orally, once daily, for 84 days (12 weeks). The primary outcome was change in total IBS-Symptom Severity Scale (IBS-SSS) score from baseline, compared to placebo...
2024: Gut Microbes
https://read.qxmd.com/read/38626998/top-studies-of-2023-relevant-to-primary-care-from-the-peer-team
#15
REVIEW
Betsy S Thomas, Danielle Perry, Samantha S Moe, Ricky D Turgeon, Jen Potter, Émélie Braschi, Nicholas Dugré, Jessica E M Kirkwood, G Michael Allan
OBJECTIVE: To provide a summary of the noteworthy medical articles published in 2023 that are relevant to family physicians. SELECTING THE EVIDENCE: Articles were chosen and ranked by the PEER (Patients, Experience, Evidence, Research) team, a group of primary care health professionals focused on evidence-based medicine. The selection process involved routine surveillance of tables of contents in high-impact medical journals and continuous monitoring of EvidenceAlerts...
April 2024: Canadian Family Physician Médecin de Famille Canadien
https://read.qxmd.com/read/38622839/amitriptyline-at-low-dose-for-burning-mouth-syndrome
#16
JOURNAL ARTICLE
Takahiko Nagamine
No abstract text is available yet for this article.
April 15, 2024: Oral Diseases
https://read.qxmd.com/read/38622838/psychological-comorbidities-are-more-prevalent-amongst-pregnant-and-postpartum-patients-with-irritable-bowel-syndrome
#17
JOURNAL ARTICLE
Yuying Luo, Christie Lee Luo, Rachel Meislin, Eunyoung Yang, Xiaotao Zhang
BACKGROUND: There is a lack of data on the epidemiology of IBS in pregnant and postpartum patients in the United States. METHODS: A retrospective claims analysis was conducted in a cohort of 1,618,379 patients with ≥1 delivery hospitalization between 2013-2019 utilizing ICD-9 and ICD-10 codes after merging inpatient and outpatient claims. Obstetric, psychological, and other medical comorbidities were also examined. KEY RESULTS: The prevalence of IBS in our cohort was 1...
April 15, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/38622462/differences-between-patients-with-heartburn-refractory-to-vonoprazan-and-those-refractory-to-proton-pump-inhibitors
#18
JOURNAL ARTICLE
Tomoaki Matsumura, Michiko Sonoda, Kenichiro Okimoto, Hang Viet Dao, Satsuki Takahashi, Naoki Akizue, Ryosuke Horio, Chihiro Goto, Akane Kurosugi, Tatsuya Kaneko, Yuki Ohta, Takashi Taida, Atsuko Kikuchi, Mai Fujie, Jun Kato, Naoya Kato
BACKGROUND: Vonoprazan, a potassium-competitive acid blocker, demonstrates more potent acid inhibition than proton pump inhibitors (PPIs). This study aimed to evaluate the effect of vonoprazan in patients with unproven gastroesophageal reflux disease (GERD) by comparing patients with vonoprazan-refractory heartburn with those with PPI-refractory heartburn. METHODS: This study included 104 consecutive patients with vonoprazan- or PPI-refractory heartburn (52 patients each), no erosive esophagitis on endoscopy and who underwent combined multichannel intraluminal impedance-pH (MII-pH) testing with vonoprazan/PPI discontinuation...
April 15, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38621241/gastroenterology-hepatology-what-you-may-have-missed-in-2023
#19
JOURNAL ARTICLE
Sama Anvari, Kayla Dadgar, Ciarán Galts, Michael Bretthauer
This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38619720/treatment-free-interval-a-novel-approach-to-assessing-real-world-treatment-effectiveness-and-economic-impact-among-patients-with-irritable-bowel-syndrome-with-diarrhea
#20
JOURNAL ARTICLE
Brian E Lacy, Patrick Gagnon-Sanschagrin, Zeev Heimanson, Rebecca Bungay, Remi Bellefleur, Annie Guérin, Brock Bumpass, Danellys Borroto, George Joseph, Ankur A Dashputre
INTRODUCTION: Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA. METHODS: Adult patients (18-64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics® Plus database (10/01/2015-12/31/2021) and classified into two mutually exclusive cohorts (i...
April 15, 2024: Advances in Therapy
keyword
keyword
2816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.